InsiderSignal.AI

InsiderSignal.ai

AKTS - Aktis Oncology, Inc.

Insider Purchase by Kim Helen Susan (Dir, 10%)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

2 months ago, Kim Helen Susan, serving as Dir, 10% owner at Aktis Oncology, Inc. (AKTS), purchased 835,000 shares at $18.00 per share, for a total transaction value of $15,030,000.00. Following this transaction, Kim Helen Susan now holds 157,387 shares of AKTS.

This purchase represents a 123.00% decrease in Kim Helen Susan's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, January 12, 2026 and publicly disclosed via SEC Form 4 filing on Monday, January 12, 2026, meaning the disclosure happened on the same day as the trade.

Aktis Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Kim Helen Susan

Dir, 10%

Helen Susan Kim is a Senior Managing Director at Vida Ventures, LLC, a venture capital firm, a position she has held since April 2019.[[5]](https://www.prothena.com/management/helen-kim/)[[7]](https://firstwordpharma.com/story/7052354) She serves as a Director and 10% Owner of Aktis Oncology, Inc. (AKTS), where she has been on the board since 2021, recently purchasing 835,000 shares on January 12, 2026, at $18.00 per share, increasing her stake to approximately 5,671,825 shares valued at over $102 million.[[1]](https://www.gurufocus.com/insider/32411/helen-susan-kim)[[2]](https://whalewisdom.com/filing/kim-helen-susan-4-2026-01-12-170010-0500-akts)[[3]](https://www.aktisoncology.com/our-team/)[[4]](https://www.marketbeat.com/instant-alerts/insider-buying-aktis-oncology-nasdaqakts-director-purchases-835000-shares-of-stock-2026-01-12/) Kim holds an MBA from the University of Chicago and a B.S. in Chemical Engineering from Northwestern University.[[3]](https://www.aktisoncology.com/our-team/)[[5]](https://www.prothena.com/management/helen-kim/) Her extensive career in biotechnology includes roles as Partner at The Column Group (2018-2019), Executive Vice President of Business Development at Kite Pharma (2014-2018, acquired by Gilead Sciences), Chief Business Officer at NGM Biopharmaceuticals (2009-2012), and CEO and President of Kosan Biosciences, which she restructured before its acquisition by Bristol Myers Squibb in 2008.[[5]](https://www.prothena.com/management/helen-kim/) She previously held senior positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs, and Chiron Corporation, and currently serves on boards including Prothena Corp. Plc (since 2022), ReCode Therapeutics, IconOVir Bio, and others.[[5]](https://www.prothena.com/management/helen-kim/)[[8]](https://www.marketscreener.com/insider/HELEN-KIM-A03AVB/)

View full insider profile →

Trade Price

$18.00

Quantity

835,000

Total Value

$15,030,000.00

Shares Owned

157,387

Trade Date

Monday, January 12, 2026

86 days ago

SEC Filing Date

Monday, January 12, 2026

HEALTHCAREBIOTECHNOLOGY

About Aktis Oncology, Inc.

Company Overview

No company information available
View news mentioning AKTS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3049399

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime